Quoin Pharmaceuticals, Ltd. American Depositary Shares
QNRX
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Last trade$3.54
Day change-$0.02 (-0.56%)
Day range$3.46 – $3.68
Volume7,137
Market cap$17M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$17.1M
Price / earnings
—
Price / book
0.6×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.35×
Profitability
Earnings per share
-$4.08
Return on assets
-56.37%
Return on equity
-68.26%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.2×
Quick ratio
7.2×
Cash ratio
2.11×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$18.82M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for QNRX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.27M
$1.85M
$1.7M
$1.42M
$1.74M
$1.74M
$1.58M
$1.35M
Research and development
$2.66M
$3.63M
$3.43M
$3.1M
$2.28M
$2.05M
$2.37M
$1.05M
Total operating expenses
$4.92M
$5.47M
$5.13M
$4.52M
$4.02M
$3.79M
$3.96M
$2.41M
Operating income
-$4.92M
-$5.47M
-$5.13M
-$4.52M
-$4.02M
-$3.79M
-$3.96M
-$2.41M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$4.87M
-$5.37M
-$5M
-$4.35M
-$3.95M
-$3.7M
-$3.81M
-$2.31M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$4.87M
-$5.37M
-$5M
-$4.35M
-$3.95M
-$3.7M
-$3.81M
-$2.31M
Net income attributable to common shareholders
-$4.87M
-$5.37M
-$5M
-$4.35M
-$3.95M
-$3.7M
-$3.81M
-$2.31M
EBITDA
-$4.9M
-$5.45M
-$5.11M
-$4.5M
-$3.99M
-$3.77M
-$3.93M
-$2.38M
Basic earnings per share
-$0.97
-$1.90
-$1.77
-$1.73
-$6.71
-$6.28
-$6.50
-$12.96
Diluted earnings per share
-$0.97
-$1.90
-$1.77
-$1.73
-$6.71
-$6.28
-$6.50
-$12.96
Recent news
Company coverage with links to the original publishers.
Quoin Pharmaceuticals reported a net loss of $6.28 per share in Q2 2025, which exceeded analyst estimates. The company is developing QRX003, a topical lotion for Netherton Syndrome, and made significant clinical and regulatory progress while increasing R&D spending.
Quoin Pharmaceuticals announced highly positive interim data from its ongoing Netherton Syndrome clinical trials, with the first subject demonstrating marked improvements across all measured endpoints after 12 weeks of treatment with the company's QRX003 topical lotion. The company is optimistic about the therapy's potential to effectively treat this rare and debilitating skin disease.
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 national conference in Albuquerque, New Mexico from June 28-30, 2024.
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its first quarter 2024 financial results before the market opens on Thursday, May 9, 2024.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.